Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q12824
UPID:
SNF5_HUMAN
Alternative names:
BRG1-associated factor 47; Integrase interactor 1 protein; SNF5 homolog
Alternative UPACC:
Q12824; O75784; O95474; Q17S11; Q38GA1; Q76N08; Q9UBH2
Background:
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1, also known as BRG1-associated factor 47, plays a pivotal role in chromatin remodeling. This protein is a core component of the BAF complex, influencing cell proliferation, differentiation, and neural development by altering chromatin structure to facilitate gene expression.
Therapeutic significance:
Linked to Rhabdoid tumor predisposition syndrome 1, Schwannomatosis 1, and Coffin-Siris syndrome 3, understanding the role of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 could open doors to potential therapeutic strategies for these complex diseases.